We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| United Therapeutics Corporation | NASDAQ:UTHR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.99 | 1.17% | 258.13 | 253.53 | 263.22 | 260.34 | 253.93 | 255.10 | 698,115 | 21:01:25 |
From May 2021 to May 2024
By Dave Sebastian
United Therapeutics Corp. and Medtronic Inc. have agreed to stop further efforts to develop and commercialize the implantable system for Remodulin, or ISR.
United Therapeutics Wednesday said the companies plan to wind down the development program and to support patients already enrolled in clinical studies of the ISR at United Therapeutics' sole expense.
The end of the efforts comes after the evolution of treatment options over the past few years, United Therapeutics said. There weren't penalties associated with the termination of the commercialization agreement, it added.
ISR has been developed in the past 12 years to deliver Remodulin injection for patients with pulmonary arterial hypertension through an implantable system developed by Medtronic. The two companies struck a commercialization agreement for the U.S. in February 2019.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
June 23, 2021 06:51 ET (10:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year United Therapeutics Chart |
1 Month United Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
